Experience with use of recombinant activated factor VII.

This is a case report of successfully treating hemorrhage with rFVIIa in four patients with factor VIII and one with factor V inhibitor. One patient was initially treated with APCC (Autoplex) and blood products unsuccessfully. The authors confirm the efficacy and safety of rFVIIa and suggest carrying out cost effectiveness analysis. Further information is required with respect to optimal therapeutic level, monitoring, and mode of administration.

– M. Aldouri.